Posts tagged AMGN


Top Analyst Encouraged By Key Amgen, Inc. (AMGN) Data

Biotechnology giant Amgen, Inc. (NASDAQ:AMGN) has released positive data for its phase II study showing …

Read more

Should You Stay Bullish on Gilead Sciences, Inc. (GILD) and Amgen, Inc. (AMGN)?

Analysts are reiterating buys on Gilead Sciences, Inc. (NASDAQ:GILD) and Amgen, Inc. (NASDAQ:AMGN), but are not …

Read more

Cowen Positive on Cytokinetics, Inc. (CYTK) as Amgen, Inc. (AMGN) Opts-in to Advance Omecamtiv to Phase 3

Cowen top analyst Ritu Baral chimes in on Cytokinetics, Inc. (NASDAQ:CYTK) after Amgen, Inc. (NASDAQ:AMGN) …

Read more

Morgan Stanley Weighs In on Valeant Pharmaceuticals Intl Inc (VRX) and Amgen, Inc. (AMGN) Following Headquarter Visit and FDA CRL

Morgan Stanley analysts were out today with commentary on healthcare giants Valeant Pharmaceuticals Intl Inc (NYSE:VRX) …

Read more

Biotech Outlook: Gilead Sciences, Inc. (GILD), Celgene Corporation (CELG), Amgen, Inc. (AMGN), Biogen Inc (BIIB), Regeneron Pharmaceuticals Inc (REGN)

Yesterday, Jennifer asked is Valeant Pharmaceuticals the proverbial canary in the coal mine for the …

Read more

Piper Jaffray Pounds the Table on Gilead Sciences, Inc. (GILD) and Amgen, Inc. (AMGN)

To kick off biotech in 2016, analyst Joshua Schimmer of Piper Jaffray pounds the table …

Read more

Unilife Corp (UNIS) Surges Following Agreement With Amgen, Inc. (AMGN)

Unilife Corp (NASDAQ: UNIS) is having an incredible day in the market today after disclosing an SEC …

Read more

Tuesday Morning’s Market Insights: Apple Inc. (AAPL), Walt Disney Co (DIS), QUALCOMM, Inc. (QCOM), Amgen, Inc. (AMGN)

Apple Inc. (NASDAQ:AAPL) was trading down 1% to about $111 in pre-market trading this morning following …

Read more

Stock Update (NASDAQ:CYTK): Cytokinetics, Inc. and Amgen Announce Positive Top-Line Results From COSMIC-HF, a Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure

Cytokinetics, Inc. (NASDAQ:CYTK) and Amgen, Inc. (NASDAQ:AMGN) announced that data from the expansion phase of …

Read more

Company Update (NASDAQ:AMGN): FDA Grants Priority Review for Amgen, Inc.’s Supplemental New Drug Application for Expanded Labeling of Kyprolis

Amgen, Inc. (NASDAQ:AMGN) announced the U.S. Food and Drug Administration (FDA) has accepted for priority review …

Read more